SarcopeniaS-TENNCT07230210
Smart Tech-Based Nutrition and Exercise for Sarcopenia Risk.
A study testing The 12-week exercise component is delivered via the dedicated Line Bot platform. It includes three progressive exercise training videos (resistance, balance) . Participants are in in people with Sarcopenia, run by HSIAO MEI LAN at 1 site in Taiwan.
Trial summary
Sarcopenia, characterized by muscle loss and weakness, is a major health issue among older adults and impacts mobility and quality of life. This study addresses the current lack of long-term, technology-assisted support for managing this condition at home. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Sarcopenia
- What is being tested?
- The 12-week exercise component is delivered via the dedicated Line Bot platform. It includes three progressive exercise training videos (resistance, balance) . Participants are in
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteTaiwan
- Study dates
- 3 Dec 2025to 31 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Score ≥ 11 on the SARC-CalF questionnaire, indicating risk of sarcopenia.
- No evident functional impairment in the limbs and able to complete handgrip strength, walking speed, and muscle mass assessments.
- Possesses basic reading, writing, and calculation abilities sufficient to understand study-related materials and complete informed consent and daily logs.
- Owns a smartphone and has used it for at least one year, with basic operational ability (e.g., sending and receiving LINE messages, scanning QR codes).
Who cannot join
- Self-reported functional impairment in any limb.
- Requires assistance from a wheelchair, walker, or cane for ambulation.
- Has an implanted cardiac pacemaker.
- Currently participating in, or planning to participate in, other physical training courses or nutrition programs during the study period.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Taiwan1 site, 1 recruiting
- Recruiting
BuddhistTCGH
Hualien City, 970473
Mei Lan Geriatric Case Manager, 0978130926, xnancye@gmail.com
About this study
Official title: The Effectiveness of Smart Technology Interventions Combining Nutrition and Exercise for Older Adults at Risk of Sarcopenia
Sarcopenia, characterized by muscle loss and weakness, is a major health issue among older adults and impacts mobility and quality of life. This study addresses the current lack of long-term, technology-assisted support for managing this condition at home. This randomized controlled trial (RCT) will evaluate a 12-week smart-technology-based program for 60 older adults at risk of sarcopenia.
Intervention:
Read more
Participants in the intervention group will receive a technology-assisted program delivered through a Line Bot system. The platform provides personalized exercise training videos, nutrition education, daily reminders, and a point-based logging system to support adherence and monitor engagement. The control group will receive standard clinic-based care.
Purpose:
The study aims to examine whether the smart technology intervention can improve muscle mass, physical performance, quality of life, and self-management ability among older adults at risk of sarcopenia.
Expected Benefit:
The digital intervention is anticipated to offer a more effective, accessible, and sustainable approach compared with standard care, providing practical support for preventing muscle decline in community-dwelling older adults
Read the detailed description
This randomized controlled trial (RCT) is designed as a 12-week intervention to evaluate the efficacy of a smart technology-assisted nutrition and exercise program for community-dwelling older adults (aged ≥ 65 years) at risk of sarcopenia. Participants (N = 60) will be randomly assigned to either the intervention group (n = 30) or the control group (n = 30). Data will be collected at baseline, week 8 (mid-intervention), and week 12 (post-intervention).
Intervention Group:
Participants will receive the 12-week program delivered through a dedicated Line Bot platform. Core components include:
Exercise Training: Three progressive exercise videos (resistance, aerobic, and balance training) designed to enhance muscle function.
Nutrition Education: One video focusing on adequate protein intake and dietary habits essential for muscle maintenance.
Smart Technology Features: The Line Bot functions as a personalized case management tool, offering daily reminders for exercise and protein intake, an interactive calculator for estimating daily protein consumption, and a digital logging system with motivational rewards to support adherence and self-management behaviors.
Control Group:
Participants will receive standard outpatient care and general health education pamphlets. They will not receive access to the Line Bot system, exercise videos, or personalized support.
Primary outcome data will be collected at week 12. Statistical analyses will include descriptive statistics and inferential methods, such as repeated measures analysis of variance (ANOVA), to examine the effectiveness of the intervention.
- Conditions
- Sarcopenia
- Being tested
- The 12-week exercise component is delivered via the dedicated Line Bot platform. It includes three progressive exercise training videos (resistance, balance) . Participants are in
- Keywords
- Sarcopenia, Smart Technology, Nutrition and Exercise Intervention
- Medical subject headings
- Sarcopenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
The 12-week exercise component is delivered via the dedicated Line Bot platform. It includes three progressive exercise training videos (resistance, balance) . Participants are inBehavioural
The 12-week progressive exercise program (resistance, aerobic, and balance training) is uniquely delivered and monitored via a dedicated Line Bot platform. This differentiates it from traditional in-person or non-interactive video programs. The platform includes interactive features like daily reminders and a digital diary to enhance adherence and support participant self-management, aiming for five exercise sessions per week.
| Study group | Role | What they receive |
|---|---|---|
| Smart Technology-Assisted Exercise and Nutrition Program | Experimental | Participants in the intervention group (n=30) will receive a 12-week smart technology-assisted combined exercise and nutrition program. The intervention is delivered via a dedicated Line Bot platform, which provides: 1) Three progressive exercise training videos (resistance, aerobic, and balance) , with the goal of participants completing five exercise sessions per week using the provided materials. 2) Nutrition education videos focusing on protein intake. 3) Interactive features including daily reminders, protein intake calculation tools, and a digital diary with motivational elements to promote adherence and self-management. Receives: Behavioral: The 12-week exercise component is delivered via the dedicated Line Bot platform. It includes three progressive exercise training videos (resistance, balance) . Participants are in |
| Standard Outpatient Care | No intervention | Participants in the control group (n=30) will receive standard outpatient care for sarcopenia risk management, which includes general health education pamphlets and regular follow-ups at the clinic. They will not receive any specialized exercise training, nutrition videos, or access to the Line Bot platform during the 12-week intervention period. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Appendicular Skeletal Muscle Mass (ASM) by Bioelectrical Impedance Analysis (BIA)
The change in skeletal muscle mass will be assessed using Appendicular Skeletal Muscle Mass (ASM), derived from bioelectrical impedance analysis (BIA). The primary endpoint is the between-group difference in the absolute change in ASM (in kilograms) from baseline to the end of the 12-week intervention (Week 12)
Measured: Baseline (Week 0), Week 8, and Final Assessment at Week 12.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Nov 2025
- Study start3 Dec 2025
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SarcopeniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants are randomized into two parallel arms: the Intervention Group (n=30) and the Control Group (n=30). Both groups will remain in their assigned arm for the entire 12-week study duration.
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- HSIAO MEI LAN
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, HSIAO MEI LAN, Buddhist Tzu Chi General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07230210
- Sponsor's protocol ID
- IRB114-215-B
- Other IDs
- IRB114-215-B
- Acronym
- S-TEN
- Status last verified
- Dec 2025
- First submitted
- 13 Nov 2025
- Last updated
- 11 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: IPD will not be shared due to the lack of dedicated infrastructure and resources for data hosting, curation, and the formal management of external data access requests in this small, investigator-initiated study.
Study at a glance
From the registry record, last updated by the sponsor on 11 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effectiveness of Smart Technology Interventions Combining Nutrition and Exercise for Older Adults at Risk of Sarcopenia
- ClinicalTrials.gov ID
- NCT07230210
- Acronym / sponsor ID
- S-TEN / IRB114-215-B
- Conditions
- Sarcopenia
- Keywords
- Sarcopenia, Smart Technology, Nutrition and Exercise Intervention
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- HSIAO MEI LANUniversity, hospital or other
- Study start
- 3 Dec 2025 (actual)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 17 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sarcopenia, characterized by muscle loss and weakness, is a major health issue among older adults and impacts mobility and quality of life. This study addresses the current lack of long-term, technology-assisted support for managing this condition at home. This randomized controlled trial (RCT) will evaluate a 12-week smart-technology-based program for 60 older adults at risk of sarcopenia.
Intervention:
Participants in the intervention group will receive a technology-assisted program delivered through a Line Bot system. The platform provides personalized exercise training videos, nutrition education, daily reminders, and a point-based logging system to support adherence and monitor engagement. The control group will receive standard clinic-based care.
Purpose:
The study aims to examine whether the smart technology intervention can improve muscle mass, physical performance, quality of life, and self-management ability among older adults at risk of sarcopenia.
Expected Benefit:
The digital intervention is anticipated to offer a more effective, accessible, and sustainable approach compared with standard care, providing practical support for preventing muscle decline in community-dwelling older adults
Detailed description
This randomized controlled trial (RCT) is designed as a 12-week intervention to evaluate the efficacy of a smart technology-assisted nutrition and exercise program for community-dwelling older adults (aged ≥ 65 years) at risk of sarcopenia. Participants (N = 60) will be randomly assigned to either the intervention group (n = 30) or the control group (n = 30). Data will be collected at baseline, week 8 (mid-intervention), and week 12 (post-intervention).
Intervention Group:
Participants will receive the 12-week program delivered through a dedicated Line Bot platform. Core components include:
Exercise Training: Three progressive exercise videos (resistance, aerobic, and balance training) designed to enhance muscle function.
Nutrition Education: One video focusing on adequate protein intake and dietary habits essential for muscle maintenance.
Smart Technology Features: The Line Bot functions as a personalized case management tool, offering daily reminders for exercise and protein intake, an interactive calculator for estimating daily protein consumption, and a digital logging system with motivational rewards to support adherence and self-management behaviors.
Control Group:
Participants will receive standard outpatient care and general health education pamphlets. They will not receive access to the Line Bot system, exercise videos, or personalized support.
Primary outcome data will be collected at week 12. Statistical analyses will include descriptive statistics and inferential methods, such as repeated measures analysis of variance (ANOVA), to examine the effectiveness of the intervention.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Participants are randomized into two parallel arms: the Intervention Group (n=30) and the Control Group (n=30). Both groups will remain in their assigned arm for the entire 12-week study duration.
| Arm | Type | Receives |
|---|---|---|
| Smart Technology-Assisted Exercise and Nutrition Program | Experimental | Behavioral: The 12-week exercise component is delivered via the dedicated Line Bot platform. It includes three progressive exercise training videos (resistance, balance) . Participants are inParticipants in the intervention group (n=30) will receive a 12-week smart technology-assisted combined exercise and nutrition program. The intervention is delivered via a dedicated Line Bot platform, which provides: 1) Three progressive exercise training videos (resistance, aerobic, and balance) , with the goal of participants completing five exercise sessions per week using the provided materials. 2) Nutrition education videos focusing on protein intake. 3) Interactive features including daily reminders, protein intake calculation tools, and a digital diary with motivational elements to promote adherence and self-management. |
| Standard Outpatient Care | No intervention | –Participants in the control group (n=30) will receive standard outpatient care for sarcopenia risk management, which includes general health education pamphlets and regular follow-ups at the clinic. They will not receive any specialized exercise training, nutrition videos, or access to the Line Bot platform during the 12-week intervention period. |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (4 listed)
- Score ≥ 11 on the SARC-CalF questionnaire, indicating risk of sarcopenia.
- No evident functional impairment in the limbs and able to complete handgrip strength, walking speed, and muscle mass assessments.
- Possesses basic reading, writing, and calculation abilities sufficient to understand study-related materials and complete informed consent and daily logs.
- Owns a smartphone and has used it for at least one year, with basic operational ability (e.g., sending and receiving LINE messages, scanning QR codes).
Key exclusion criteria (4 listed)
- Self-reported functional impairment in any limb.
- Requires assistance from a wheelchair, walker, or cane for ambulation.
- Has an implanted cardiac pacemaker.
- Currently participating in, or planning to participate in, other physical training courses or nutrition programs during the study period.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| The 12-week exercise component is delivered via the dedicated Line Bot platform. It includes three progressive exercise training videos (resistance, balance) . Participants are inThe 12-week progressive exercise program (resistance, aerobic, and balance training) is uniquely delivered and monitored via a dedicated Line Bot platform. This differentiates it from traditional in-person or non-interactive video programs. The platform includes interactive features like daily reminders and a digital diary to enhance adherence and support participant self-management, aiming for five exercise sessions per week. | Behavioural | Smart Technology-Assisted Exercise and Nutrition Program |
Primary outcome
Appendicular Skeletal Muscle Mass (ASM) by Bioelectrical Impedance Analysis (BIA)
Time frame: Baseline (Week 0), Week 8, and Final Assessment at Week 12.
The change in skeletal muscle mass will be assessed using Appendicular Skeletal Muscle Mass (ASM), derived from bioelectrical impedance analysis (BIA). The primary endpoint is the between-group difference in the absolute change in ASM (in kilograms) from baseline to the end of the 12-week intervention (Week 12)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Dec 2025.
- Individual participant dataSharing planned: No. IPD will not be shared due to the lack of dedicated infrastructure and resources for data hosting, curation, and the formal management of external data access requests in this small, investigator-initiated study.
Related trials for Sarcopenia
Active, not recruitingObservational study
Possible Sarcopenia, Sarcopenia, and Functional Status in Patients With Primary Sjögren's Syndrome
Primary Sjögren Syndrome, Sarcopenia
Not yet recruiting
PROfiles of FGF-19 Post-prandial Secretion in Older Adults With Frailty and Without Frailty
Frailty, Sarcopenia
Recruiting
Resistance vs Aerobic Prehabilitation Before Colorectal Cancer Surgery
Colorectal Cancer, Colorectal Neoplasms
Recruiting
Effects of a Community-based Multicomponent Physical Exercise Program on Physical Function, Frailty, and Sarcopenia in Older Adults From the Municipality of Santoña: a Quasi-experimental Study.
Frailty/Sarcopenia, Frailty in Older Adults
Not yet recruiting
Creatine and Muscle Health in Madrid's Walking Footballers.
Muscle Adaptation, Body Composition
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing The 12-week exercise component is delivered via the dedicated Line Bot platform. It includes three progressive exercise training videos (resistance, balance) . Participants are in in people with Sarcopenia, run by HSIAO MEI LAN at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mei Lan Hsiao, RN (+886-978130926, xnancye@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Appendicular Skeletal Muscle Mass (ASM) by Bioelectrical Impedance Analysis (BIA) (time frame: Baseline (Week 0), Week 8, and Final Assessment at Week 12.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Dec 2025.